The NeoSphere study compared docetaxel + HP with docetaxel + trastuzumab (H) alone in operable (T2–3, N0–1, M0), locally advanced (T2–3, N2–N3, M0; T4a–c, any N, M0), or inflammatory (T4d, any N, M0) HER2+ breast cancer (N = 417). The gene discussed is ERBB2; the disease is breast cancer.